All In Biotech

Drug Trial Radar · NCT00164736

Breastfeeding, Antiretroviral, and Nutrition Study

HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health

Last checked: Nov 19, 2026Latest source record: Apr 23, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,369 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,369

Actual

Start

Mar 2004

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Sponsor type
Federal agency
Collaborators
University of North Carolina, Chapel Hill; Kamuzu Central Hospital
First posted
Sep 14, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 14 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a comparative clinical trial among HIV-infected women and their infants to determine: 1. the benefit of nutritional supplementation given to women during breastfeeding 2. the benefit and safety of antiretroviral (ARV) medications given either to infants or to their mothers to prevent HIV transmission during breastfeeding 3. the feasibility of exclusive breastfeeding followed by early, rapid breastfeeding cessation

Conditions

  • HIV Infections

Interventions

  • Maternal zidovudine/lamivudine/lopinavir-ritonavirDrug

    Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.

  • Infant nevirapineDrug

    Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg. To 28 weeks while breastfeeding.

  • Maternal protein and calorie supplementDietary supplement

    High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postpartum weight loss between delivery and 28 weeksTime frame: between delivery and 28 weeks
  2. Infant HIV status at 28 weeks. (Infants found to have HIV at birth or 2 weeks after delivery will have been disenrolled.)Time frame: birth to 28 weeks
  3. Exclusive breastfeeding and breastfeeding cessation by 28 weeksTime frame: birth to 28 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kamuzu Central Hospital, Bottom Hospital

    Lilongwe, Malawi

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.